AI-Stem Cell Researcher, Co-Founder@CTO

Minjun Kang

Hello, I am Minjun Kang, the CTO and Co-founder of NOAH’S FARM PTE. LTD. in Singapore, and a Ph.D. candidate in Medicine and Computer Science at Seoul National University, where I previously earned my Master of Medicine degree summa cum laude honors (as Valedictorian) and an Excellent Thesis Honor.


My research was recognized as one of the Top 5 flagship R&D achievements among Korea’s top 30 medical research outcomes. I previously worked as a biomedical researcher at Seoul National University Hospital in Korea and hold a B.S. in Biomedical Sciences from CHA University.

AI, Stem Cell Researcher


  • -
    NOAH'S FARM PTE. LTD. (Singapore), Co-founder/CTO

    Noah’s Farm has developed and is advancing proprietary AI models—“N-Palette” and “N-Block”—that predict and generate novel flavor molecules. Our team, comprising top talent from Seoul National University, UC Berkeley, Cambridge University, and Korea University, has demonstrated rapid execution capabilities, recently achieving the successful generation and rigorous validation of a flavor molecule indistinguishable from blueberry. Raised KRW 4 billion (Pre-seed) from Sazze Partners (Silicon Valley) and Company K Partners (Korea).


    Homepage : https://www.noahs-farm.xyz/.

  • -
    Seoul National University Hospital (Korea), Biomedical Researcher

    I worked in the Cardiac Differentiation Team of the Cardiovascular Laboratory at the Biomedical Research Institute, with a focus that bridges computer science and stem cell biology.


    In computer science, my research centers on Transformer-based generative AI to design novel ligands for G protein–coupled receptors (GPCRs)—one of the novel therapeutic target classes. By combining advanced Transformer architectures with drug discovery pipelines, I develop new ligand candidates with high potential for stem cell–based therapeutics.


    In stem cell biology, I specialize in advanced cardiac differentiation protocols for both mouse embryonic stem cells and human-induced pluripotent stem cells (iPSCs). My expertise extends to the preservation of pluripotent stem cells, the development of lentiviral overexpression vectors, and the creation of conditional knockout transgenic mice for cardiovascular research.

  • -
    ALTERNATE (Korea), Founder, CEO

    I founded a cultured meat company dedicated to promoting human health through cellular agriculture. In 2022, the company was selected as a finalist in the National Development Project (Topic: Cultured Meat) organized by the Korean Chamber of Commerce and Industry. In the same year, we successfully completed the Startup Pre-School Program, validating our technological approach and business potential.

Education


  • Seoul National University (Korea), Ph.D Candidate

    -

    Medicine & Computer Science

    a. Studied research on generative AI models for discovering heart-specific GPCR ligands.

    b. Selected as Top 5 Flagship R&D Achievement among Korea’s Top 30 Medical R&D Outcomes by the Korean Ministry of Health and Welfare (2025)

    c. Awarded the Full Tuition Ph.D Scholarship by the Kwanak Foundation of SNU

  • Seoul National University (Korea), Master of Medicine

    -

    a. Studied the mechanism of a GPCR with potential as a target for gene and stem cell therapies.

    b. Graduated with highest honors in class, recognized for academic excellence. (Valedictorian)

    c. Received the Excellent Thesis Honor.

  • CHA University (Korea), B.S (Biomedical Science)

    -

    a. Studied undergraduate research in stem cell biology.

    b. Affiliated with Cha Medical Group.

Interests

Studied stem cells for my bachelor's degree, GPCRs for my master's, and generative AI models in medicine for my Ph.D. to discover heart-specific ligands.

  • Journals

    -

    1. 1st Author

    a. Minjun Kang, Choon-Soo Lee, HyunJu Son, Jeongha Lee, Jaewon Lee, Hyun Ju Seo, Moo-kang Kim, Murim Choi, Hyun-Jai Cho, and Hyo-Soo Kim. Latrophilin-2 deletion in cardiomyocyte disrupts cell junction, leading to D-CMP -Circulation Research (Top-Ranked Journal in cardiovascular research, AHA Journal)



    1. Co-Author


    a. Jeehoon Kang, Hyun Ju Seo, HyunJu Son, Minjun Kang, Jaewon Lee, Eun Ju Lee, Hyun-Jai Cho, Hyo-Soo Kim. Newly-engineered angiopoietin-1 as a cell-priming agent for CVD - Cellular and Molecular Life Sciences (IF 6.2, 2025)


    b. Jin-Woo Lee, Choon-Soo Lee, HyunJu Son, Jaewon Lee, Minjun Kang, Jinho Chai, Hyun-Jai Cho, Hyo-Soo Kim. SOX17-mediated LPAR4 expression plays a pivotal role in cardiac development and regeneration after myocardial infarction -Experimental & Molecular Medicine (Nature Portfolio, 2023)


    c. Choon-Soo Lee, Hyun-Jai Cho, Jin-Woo Lee, Hyun Ju Son, Jaewon Lee, Minjun Kang, Hyo-Soo Kim. The G Protein-Coupled Receptor Latrophilin-2, A Marker for Heart Development, Induces Myocardial Repair After Infarction -Stem Cell Translational Medicine, 2022


    Google Scholar LINK

  • Honor and Scholarship

    -

    a.Top 5 Flagship R&D Achievement among Korea’s Top 30 Medical R&D Outcomes - Korea Health Industry Development Institute (KHIDI), 2025

    b.Excellent Thesis Honor - Seoul National University, 2024

    c.Excellent Paper Honor - Basic Science Society of the Korean Heart Association, 2024

    d.Full Tuition Ph.D Scholarship - the Gwanak Foundation of Seoul National University

    e.BK21 Scholarship - Seoul National University

Interview


  • Biological Research Information Center, BRIC

    -

    BRIC Hanbitsa Interview

    LINK

Press Release


  • Identified a novel mechanism

    -

    At Seoul National University Hospital (Korea)

    Link

  • Top 5 Medical R&D Achievement

    -

    By Ministry of Health and Welfare, Korea Health Industry Development Institute.

    Link

  • NOAH'S FARM Pre-Seed

    -

    Raised KRW 4 billion (Pre-seed) from Sazze Partners (Silicon Valley) and Company K Partners (Korea).

    LINK